Management attributed the Q1 revenue shortfall to a discrete $8 million gross-to-net modeling dynamic for VEVYE, where a surge in high-deductible patient volume outpaced initial financial assumptions. Underlying demand for VEVYE remains robust, with new prescriptions growing 25% sequentially despite a broader branded dry eye market that declined 18% during the same period. The company completed a major commercial expansion, doubling the VEVYE sales force and tripling the TRIESENCE team to convert accelerati ...